Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
61 hedge funds and large institutions have $171M invested in Kindred Biosciences, Inc. in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 14 closing their positions.
16% more capital invested
Capital invested by funds: $148M → $171M (+$23.8M)
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
9% less funds holding
Funds holding: 67 → 61 (-6)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $102K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.31M |
| 2 |
State Street
Boston,
Massachusetts
|
+$427K |
| 3 |
NSEDCP
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
|
+$391K |
| 4 |
BlackRock
New York
|
+$334K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$3M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$2.45M |
| 3 |
CC
Cannell Capital
Alta,
Wyoming
|
-$1.54M |
| 4 |
PGC
Pacific Grove Capital
San Francisco,
California
|
-$1.48M |
| 5 |
Renaissance Technologies
New York
|
-$779K |
KIN Hedge Fund Activity: Q4 2017 in Review
61 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q4 2017, worth a combined $171M — up 16% from $148M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KIN and 8 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 18 added.
The largest buyer was Vanguard Group, adding an estimated $1.31M. The largest seller was Ariel Investments, cutting an estimated $3M.
- 61 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q4 2017, down from 67 in Q3 2017.
- Funds reported $171M of Kindred Biosciences, Inc. stock for Q4 2017, up 16% quarter-over-quarter.
- 8 funds opened new Kindred Biosciences, Inc. positions in Q4 2017 and 14 closed out, a net change of -6 holders.
- The largest Kindred Biosciences, Inc. buyer in Q4 2017 was Vanguard Group, an estimated $1.31M added.
- The largest Kindred Biosciences, Inc. seller in Q4 2017 was Ariel Investments, an estimated $3M sold.
Based on aggregated 13F filings for Q4 2017.